FLT3 and acute myeloid leukemia: Finally, in a PDX model of AML cells harboring MLL-AF9 and FLT3 mutation, co-treatment with ziftomenib and venetoclax or OTX015 yielded significantly greater reduction in AML burden and improvement in survival compared to each agent alone without significant host toxicity.